Test Price
2,800 AED✅ Home Collection Available
SLC25A4 Gene Test – Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 2 (Autosomal Dominant) – Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
Clinical Assurance: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139). Compliant with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability.
Insurance Direct Billing Verification: WhatsApp +971 54 548 8731
Test Overview & Methodology
The SLC25A4 gene test identifies autosomal dominant mutations causing progressive external ophthalmoplegia with mitochondrial DNA deletions type 2 – a rare neuromuscular disorder. Using Next‑Generation Sequencing (NGS) on whole blood or extracted DNA, this targeted analysis delivers unprecedented accuracy for clinical diagnosis and family risk assessment.
| Feature | Our Test (NGS – SLC25A4) | Mitochondrial Genome Panel (Alternative) |
|---|---|---|
| Precision | Single‑gene resolution; 99.9% analytical sensitivity | Broader coverage, lower per‑gene depth |
| Methodology | Illumina NGS + Sanger confirmation | Next‑generation whole mitochondrial DNA sequencing |
| Turnaround Time | 3–4 weeks | 6–8 weeks |
Physician Insight & Safety Protocols
“The SLC25A4 mutation analysis is a cornerstone for diagnosing autosomal dominant progressive external ophthalmoplegia with mitochondrial deletions. A positive result must be correlated with clinical findings, electromyography, and muscle biopsy. Genetic counselling is mandatory before and after testing to ensure patients understand the implications for themselves and their families.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Medication Safety Notice
Do not discontinue any prescribed medication, especially mitochondrial support supplements or antiepileptics, without consulting your treating physician. Abrupt changes may precipitate metabolic crisis.
Exclusion Criteria & Emergency Red Flags
- Patients with active systemic infection or acute metabolic decompensation should postpone collection.
- If you experience sudden vision loss, severe muscle weakness, difficulty swallowing, or cardiac irregularities, seek emergency care immediately – do not wait for test results.
- Pregnant individuals may still undergo testing after consulting their obstetrician and genetic counsellor; results interpretation may be adjusted.
Patient FAQ & Clinical Guidance
1. How does this NGS test confirm progressive external ophthalmoplegia type 2?
This targeted NGS assay sequences the entire coding region of the SLC25A4 gene, detecting single nucleotide variants, small insertions/deletions, and copy number changes that cause autosomal dominant progressive external ophthalmoplegia with mitochondrial deletions type 2, providing a molecular confirmation in over 95% of clinically suspected cases. The analysis includes bioinformatic filtering against population databases and in‑house curated variant libraries to ensure only disease‑associated mutations are reported. A positive result enables accurate genetic counselling and cascade screening of at‑risk family members.
2. What does the 2,800 AED fee include and how is the sample collected?
The 2,800 AED package covers a mandatory 30‑minute pre‑test genetic counselling session, a hospital‑grade home phlebotomy visit using cold‑chain transport, laboratory processing with NGS, and a post‑test clinician‑led telephonic interpretation session. You may provide a standard venous blood sample (EDTA tube) or a single drop of blood on an FTA card – both equally acceptable. The entire process is conducted by DHA‑licensed professionals under ISO 9001:2015 protocols, and results are delivered in 3–4 weeks.
3. Can I use this test for my child or asymptomatic relative?
Testing of minors and asymptomatic at‑risk relatives is strictly regulated under UAE Federal Decree-Law No. 45 of 2021 (PDPL) and Federal Law No. 2 of 2019 on ICT in Health. Such testing requires prior genetic counselling, explicit parental consent, and approval by a DHA‑recognised clinical genetics service to ensure ethical and legal compliance. For asymptomatic adults, presymptomatic testing is available only after comprehensive genetic counselling and psychological assessment. The laboratory adheres to the highest privacy standards mandated by UAE law, and all results are encrypted end‑to‑end.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical testing and patient consent processes comply with Federal Decree-Law No. 4 of 2016 on Medical Liability. The facility is licensed under DHA License No. 1143 and operates from Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | SLC25A4 Gene Test (Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 2, Autosomal Dominant) |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card – VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger Confirmation |
| ICD-10-CM Code | G71.3, H49.819, Z14.8 |
| LOINC Code | 82939-2 |
| DHA Facility License & Laboratory Address | DHA License 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians